Cyberonics Faces Challenge Of Expectations In Wake Of Failed Medtronic Bid
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics likely will face increased pressure to execute its long term business plan and meet rising shareholder expectations now that Medtronic's unwelcome $480 mil. acquisition proposal has been withdrawn.
You may also be interested in...
Medtronic Neuro Biz Stimulation Prospects Include Epilepsy, OCD Treatments
The potential of Medtronic's deep brain stimulation technology to treat epilepsy will be evaluated in a 10-center, 124-patient pivotal trial
Medtronic Neuro Biz Stimulation Prospects Include Epilepsy, OCD Treatments
The potential of Medtronic's deep brain stimulation technology to treat epilepsy will be evaluated in a 10-center, 124-patient pivotal trial
Cyberonics NCP Depression Indication May Be Tonic For Medtronic Blues
Cyberonics will create a separate 214-member depression sales and marketing team for the NCP NeuroCybernetic Prosthesis vagus nerve stimulation system and have it in place by the beginning of 2002, or roughly six months before the company expects FDA approval for the indication, CEO Skip Cummins reported at a Sept. 21 teleconference.